Guardant Health, Inc. (NASDAQ:GH)
| Market Cap | $19.73B+31.1% |
| Revenue (ttm) | $1.28B+41.7% |
| Net Income | -$485.07M-21.6% |
| EPS | -$3.68-14.6% |
| Shares Out | 135.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,757,526 |
| Open | $143.10 |
| Previous Close | $145.59 |
| Day's Range | $141.00 - $148.26 |
| 52-Week Range | $74.55 - $191.05 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | $203.40(+39.48%) |
| Earnings Date | Feb 18, 2027 |
About GH
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
6 firms rating GH in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 18, 2027Earnings report
$GH stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of GH by members of U.S. Congress
| Jonathan JacksonHouse / D | Purchase$15.00K – $50.00K | Sep 28, 2026 |
| Sheldon WhitehouseSenate / D | Purchase$1.00K – $15.00K | Nov 21, 2025 |
Recently reported changes in GH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by GH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
GH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
GH Revenue by Segment or Geography
| Oncology | $231.26M | 64.07% |
| Screening | $67.61M | 18.73% |
| Biopharma and data | $58.97M | 16.34% |
| Licensing and other | $3.13M | 0.87% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New GH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to GH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in GH
| VTIVanguard Morningstar Total Stock Market ETF | $571.49M |
| VBVanguard Morningstar Small-Cap ETF | $511.04M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $286.00M |
| VXFVanguard Extended Market ETF | $272.11M |
| IWPiShares Russell Mid-Cap Growth ETF | $94.07M |
| ARKGARK Genomic Revolution ETF | $90.25M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from GH’s recent data — informational, not investment advice
What’s Behind the Score
News check: Product launch, raised guidance, and successful debt offering outweigh valuation concerns and insider selling.
Recent Insider Activity
Insider Score Trend Over Time
-35.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| HELX | Franklin Genomic Advancements ETF | 8.63% |
| GNOM | Global X - Genomics & Biotechnology ETF | 5.09% |
| LRNZ | TrueShares Technology, AI and Deep Learning ETF | 5.03% |
| ARKG | ARK Genomic Revolution ETF | 4.85% |
| HLTH | Tema Healthcare AI ETF | 4.60% |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 4.53% |
| SPIT | F/m Emerald Special Situations ETF | 3.75% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 3.74% |
| CTAG | Calamos Timpani Active SMID Growth ETF | 3.61% |
| MEDI | Harbor Health Care ETF (MEDI) | 3.39% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 3.39% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 3.37% |
Weight is the stock’s share of each fund’s holdings.
